OBJECTIVES: Transcatheter aortic valve implantation (TAVI) has reoriented the treatment of aortic stenosis (AS) for high-risk patients. Little is known about late outcome after TAVI, surgical aortic valve replacement (AVR) or medical treatment in a single centre. We report patients' characteristics, early and 6-year survival rates after the three therapeutic strategies, and the evolution over time. We also analysed predictive factors of mortality after TAVI or surgical AVR.
INTRODUCTION
Degenerative aortic stenosis (AS) is the most frequent valvular heart disease in western countries due to ageing of the population. Natural history of AS is unfavourable with a median survival of <5 years once symptoms appear and even <2 years in cases of congestive heart failure [1] . No medical treatment has been shown to be effective on survival and treatment relies on aortic valve replacement (AVR) [1] , the reference treatment being surgical AVR [2] , which improves survival and functional status.
However, in elderly patients with comorbidities, operative mortality dramatically increases (between 4 and 8% after 70 years) and one-third of patients are not referred to surgical AVR [3] . Transcatheter aortic valve implantation (TAVI) has emerged as a valid alternative solution in these patients [4] [5] [6] [7] [8] [9] . The guidelines confirm the role of TAVI for high-risk patients after the assessment by the Heart Team [2, 10] .
The emergence of TAVI has increased the number of very highrisk patients with AS referred for therapeutic management over time and also increased the number of procedures of percutaneous balloon aortic valvuloplasty (PBAV) [2] . Few data exist about patients referred for their symptomatic AS who could not be treated by TAVI or surgery. The 3-and 5-year outcomes after randomization between TAVI and medical treatment have recently been published [11, 12] , but few long-term data on everyday life patients contraindicated to TAVI are available.
Moreover, several randomized studies have compared TAVI with surgical AVR with a non-inferiority [9, 13] or even a superiority of TAVI over surgical AVR in selected patients [7] . However, few data exist on long-term follow-up for these two treatments [13] .
The aim of this study was, therefore, to evaluate the therapeutic management of real-life high-risk patients referred for symptomatic AS. We also analysed the evolution of the three treatment strategies (TAVI, surgery and medical treatment) from 2006, the beginning of the TAVI experience, through 2010 by which time it had become a recognized treatment, along with the survival of patients according to their allocated treatment group. Patients in the medical group were treated with either aortic balloon dilatation or drugs only. We provided long-term follow-up, up to 6 years, and studied the predictive factors of early and late outcome for patients who benefited from an invasive strategy (TAVI or surgery).
MATERIALS AND METHODS

Population
This study is a prospective single-centre registry of 478 consecutive high-risk patients who were referred to our institution from October 2006 to December 2010 with severe symptomatic AS without other severe valve disease. High risk was defined according to the surgical risk scores: a logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) >20% or an STS (Society of Thoracic Surgeons) score >10% and/or according to comorbidities not taken into account in usual risk scores, after a multidisciplinary evaluation by the Heart Team. To assess comorbidities, the Charlson comorbidity index was used in addition to usual risk scores (Supplementary Table 1 ).
All patients provided written informed consent for the procedure and the study was approved by the local review committee.
Measurements
Transthoracic echocardiographic examinations were systematically performed at baseline and at Day 7 after intervention (TAVI or surgical AVR) by experienced echocardiographers. The echocardiographic measurements of aortic valve area, systolic pulmonary artery pressure (PAP) and left ventricular ejection fraction (LVEF) were obtained according to the guidelines [2, 10] . The severity of aortic regurgitation (AR) and mitral regurgitation was graded from 0 to 4 using an integrative approach as recommended [10, 14] .
Follow-up
Data were prospectively entered in a computerized database [15] . Follow-up was conducted through clinical visits, phone contact with the referring cardiologist or direct phone contact with the patient. Follow-up was concluded in January 2015. Patients were considered lost to follow-up if they were still alive, but their last contact occurred before June 2014. Follow-up was complete in 468 patients (98%).
The mean follow-up was 3.6 ± 0.2 years for the patients treated by TAVI, 4.8 ± 0.4 years for the patients treated by surgery and 1.3 ± 0.2 years for the patients under medical treatment, and maximum follow-up was 6 years.
For the analysis of the predictive factors of late survival after TAVI or surgical AVR, we considered only patients who survived until Day 30 after the procedures to avoid the impact of factors implicated in 30-day mortality.
Procedures
All the procedures were performed in our institution by a dedicated experienced team (either surgical or interventional).
-Surgical AVR was performed through median sternotomy under extracorporeal circulation. No other combined valvular surgery was performed in our population. -For TAVI implantation, both the Edwards SAPIEN and the Medtronic CoreValve System were used in the study. The Edwards SAPIEN was used from the beginning of our experience, whereas the Medtronic CoreValve System was available only after November 2008. Patients were selected for either a transfemoral or transapical approach on the anatomy of iliofemoral arteries. Transfemoral access was favoured whenever possible. -Aortic balloon dilatation was usually performed under local anaesthesia, with fluoroscopic guidance, via the transfemoral retrograde approach. The balloon diameter was chosen according to the measurement of the annulus diameter by echocardiography (ratio 1/1).
For TAVI and PBAV, rapid right ventricular pacing was used to stabilize the valve or the balloon during inflation. At the end of the procedure, patients were transferred to the intensive care unit.
Outcome
The event taken into account during follow-up was death. The cause of death was classified as cardiac or non-cardiac. If the cause remained unknown, it was considered to be cardiovascular related according to the VARC-2 criteria [16] . For postprocedural outcome, we considered only infections requiring antibiotic treatment.
Statistical analysis
Quantitative variables were expressed as mean ± SD. Qualitative variables were expressed as numbers and percentages. In cases in which more than two groups were compared for quantitative variables, we used an analysis of variance test followed, if P < 0.05, by a modified Bonferroni correction test. For qualitative variables, we used a χ 2 test.
Survival curves for time-dependent variables were obtained with Kaplan-Meier estimates and comparisons between the different groups with a log-rank test.
The univariate analysis of factors associated with mortality was performed using a Cox model and predictive factors with P < 0.10 were included in a multivariate Cox analysis with backward selection using a threshold of P < 0.05. Only the variables that were statistically significant in the final multivariate Cox regression model were reported in Supplementary Tables 2-5 .
The results were considered significant when two-sided P-values were <0.05. All analyses were performed with the SPSS statistical software package (SPSS version 19, SPSS Inc., Chicago, IL, USA).
RESULTS
Population
Of the 478 consecutive patients referred for symptomatic AS, 253 had a TAVI (26 patients with a bridge PBAV), 102 a surgical AVR (6 patients with a bridge PBAV) and 123 had medical treatment, after assessment by the Heart Team. Among the patients medically treated, 33 underwent PBAV, whereas 90 had drug therapy alone.
The flowchart of the population is illustrated in Fig. 1 . The main characteristics of the patients in each of the three treatment groups are detailed in Table 1 .
The patients in the three groups were at high surgical risk as attested by a mean logistic EuroSCORE >20% for each group. However, patients under medical treatment had significantly higher risk scores than patients treated surgically or with TAVI (P < 0.05 for both the ES and the STS score). These patients were older, with a lower body mass index, more frequent diabetes under insulin treatment and more severe renal failure than the other two groups. Regarding echocardiographic data, they presented with more advanced cardiac disease, with a significantly higher systolic PAP and a more impaired LVEF (P < 0.001 for both).
When comparing TAVI and surgical groups, patients in the TAVI group had significantly more comorbidities as assessed by a higher Charlson index, a higher systolic PAP, more prior radiation therapy, chronic obstructive pulmonary disease (COPD) and atrial fibrillation (AF).
Periprocedural results for transcatheter aortic valve implantation and surgical aortic valve replacement
Among the patients treated with TAVI, 186 patients (74%) were implanted with an Edwards Sapien and 67 (26%) with a Corevalve. The transfemoral route was used in 171 cases (68%).
A bioprosthesis was implanted in 92% of surgically treated patients.
There was no procedural death in the surgical group, whereas 5 patients (2%) died in the TAVI group without statistical significance (P = 0.16).
The echocardiographic evaluation at Day 7 after the procedure showed paraprosthetic AR ≥2/4 only in the TAVI group: 23 patients (10%) versus none in the surgery group (P = 0.002). Systolic PAP was also significantly higher in the TAVI group (43.3 ± 13.3 vs 39.1 ± 8.6, P = 0.01), whereas the mean aortic gradient was lower (10.8 ± 4.3 vs 13.9 ± 6.2, P < 0.0001) ( Table 2) .
30-Day outcome after transcatheter aortic valve implantation or surgery
There was no significant difference between the two groups for the majority of postprocedural complications listed in Table 2 . We found more frequent AF after surgery (46 vs 14%, P < 0.0001) and more frequent pericardial effusions (16 vs 6%, P = 0.002) when compared with the TAVI group.
There was, however, no significant difference between the two groups regarding 30-day survival: 91 ± 2% in the TAVI group and 88 ± 3% in the surgical AVR group [hazard ratio (HR) for TAVI vs surgery: 1.37; 95% CI: 0.73-2.58; P = 0.32], as illustrated in Supplementary Figure 1 .
We analysed the predictive factors of early mortality (until 30 days after the procedure) in both groups. In multivariate analysis, we found two predictive factors of early death after TAVI: a higher troponin peak (adjusted HR: 1.01; 95% CI: 1.01-1.01 per µg/l; P < 0.0001) and the occurrence of infectious complications (adjusted HR: 23.6; 95% CI: 6.4-87.3; P < 0.0001). The detailed results of the univariate and multivariate analyses are provided in Supplementary Table 2 .
For the surgical AVR group, the predictive factors in multivariate analysis that we found were: a lower creatinine clearance (adjusted HR: 0.99; 95% CI: 0.98-1.00 per ml/min increase; P = 0.007) and a higher troponin peak after surgery (adjusted HR: 1.01; 95% CI: 1.00-1.02; P = 0.002), as detailed in Supplementary Table 3 .
Late survival
Overall survival for the three groups of treatment is presented in Fig. 2 .
Transcatheter aortic valve implantation versus surgery
The 6-year survival rate was significantly higher in the surgical group than in the TAVI group in univariate analysis (40 ± 6 vs 32 ± 4%, HR for TAVI vs surgery: 0.71; 95% CI: 0.53-0.97; P = 0.03). There was no longer any significant difference after adjustment on the Charlson comorbidity index between the two groups (P = 0.68; HR for TAVI vs surgical treatment: 0.94; 95% CI: 0.68-1.29). The majority of deaths were from non-cardiac causes with only 40% cardiac death in the TAVI group and 39% in the surgery group.
In multivariate analysis, we found seven predictive factors of late mortality in the TAVI group. The three preprocedural variables were: a history of cancer (adjusted HR: 1.93; 95% CI: 1.31-2.83; P = 0.001), diabetes (adjusted HR: 1.82; 95% CI: 1.23-2.69; P = 0.003) and New York Heart Association (NYHA) class III or IV (adjusted HR: 2.54; 95% CI: 1.35-4.77; P = 0.004). The four postprocedural variables were: a higher systolic PAP (adjusted HR: 1.02; 95% CI: 1.00-1.03 per mmHg; P = 0.006), a periprosthetic AR ≥2/4 (adjusted HR: 2.56; 95% CI: 1.32-4.97; P = 0.005) and a lower mean transaortic gradient (adjusted HR: 0.94; 95% CI: 0.90-0.99 per mmHg; P = 0.02), as assessed by echocardiography at Day 7, and the occurrence of AF (adjusted HR: 2.01; 95% CI: 1.23-3.26; P = 0.005).
In the surgical group, we identified five predictive factors of late mortality. The four preprocedural variables were: a history of 
Medical treatment group
The patients under medical treatment presented a significantly worse survival rate compared with those who underwent TAVI or surgery (P < 0.001). The mortality was particularly high in this group during the first year after patients' inclusion with a 1-year survival of 30%, whereas it was >75% for the TAVI and surgery groups. These results are consistent with patients' comorbidities as assessed by higher risk scores and Charlson index in comparison with TAVI or surgical groups. In addition, 23 patients (19%) were in poor general state precluding any intervention and 16 (13%) had severe dementia.
Percutaneous balloon aortic valvuloplasty
Among the 478 patients referred to our institution for symptomatic AS, 65 (14%) underwent a PBAV. Of these patients, 32 were treated using TAVI or a surgical AVR after PBAV (bridge PBAV), whereas 33 had no other intervention and were treated medically (compassionate PBAV). The main characteristics of the two subgroups of patients who had PBAV are detailed in Table 3 . This population was at extremely high risk with a mean logistic EuroSCORE of 27% for the bridge PBAV group and 38% for the compassionate PBAV group. Patients who had compassionate PBAV had more comorbidities, in particular more severe renal failure as reflected by creatinine clearance, than patients of the bridge PBAV group (P = 0.003).
Patients who were treated using PBAV before TAVI or surgical AVR (bridge PBAV) presented good long-term survival, which was not statistically different from patients treated by TAVI or surgery as a first-line treatment, as illustrated in Fig. 3A .
On the other hand, patients who had compassionate PBAV had the lowest survival rate with <1 in 4 patients still alive 1 year after PBAV (Fig. 3B) . Besides the extremely high-risk profile of these patients, postprocedural complications contributed to death in 6 patients: cardiogenic shock due to complete atrioventricular block in 1, intraventricular obstruction in 2, acute kidney failure due to tubular necrosis in 1 and aspiration pneumonia in 2. Compassionate PBAV thus does not improve survival over medical drug therapy, as attested by Fig. 3B . Patients undergoing compassionate PBAV had a higher risk profile than patients treated with medical therapy alone (Supplementary Table 6 ).
Temporal trends
The evolution of the age and risk score in patients referred for severe symptomatic AS as well as their treatment allocation from 2006 to 2010 is illustrated in Fig. 4 .
The recruitment of patients increased over time with 59 patients in 2007 and more than twice as many (160 patients) in 2010. This is due to the development of TAVI which led to the referral of patients 
DISCUSSION
This single-centre registry on 478 consecutive high-risk patients referred for therapeutic decision-making on their symptomatic AS, between 2006 and 2010, illustrates the management of severe AS by the Heart Team in current practice in this particular population.
Population
We included only high-risk patients, as defined by elevated risk scores (logistic EuroSCORE > 20% or STS score > 10%) and/or severe comorbidities with a contraindication to surgery or a high surgical risk according to the Heart Team. Our population characteristics are in line with the literature with risk scores lower than in the PARTNER 1 trial [12] but higher than in the first published CoreValve US trial [7] . This was an observational study and the patients were not randomized for treatment group allocation. We thus observed more comorbidities in the patients in the TAVI group than those in the surgical AVR group which reflects everyday life practice. Besides percutaneous or surgical AVR, we also analysed the patients contraindicated for TAVI or surgery, who accounted for 26% of all patients referred for AS in the present study. Very few data exist on this medically treated population and long-term follow-up is available from only one randomized trial which may not reflect current practice [12] . Patients in the medical treatment group had significantly more severe comorbidities than patients with either surgical AVR or TAVI. Their survival rate illustrates the extremely poor prognosis of severely symptomatic AS but also the 'too late' referral of these patients. Their mean LVEF was <45% and systolic PAP >50 mmHg, reflecting an advanced cardiac condition. In line with these observations, 1 out of 3 patients presented with severe comorbidities precluding any intervention. Among them, the most frequent were poor general status and dementia, which may also contribute to a delay in referral for AS treatment. In this context, the expected gain of length and quality of life is more questionable.
Transcatheter aortic valve implantation and surgery: 30-day procedural outcomes
The 30-day mortality rates according to Kaplan-Meier estimates were 9% in the TAVI group and 12% for surgical AVR, which is consistent with the literature for high-risk patients and preliminary experience of TAVI [7, 9] , without any significant difference between groups. Regarding 30-day events, we found, as in the PARTNER trial, more frequent AF after surgical management when compared with TAVI [9] . The predictive factors of early death were: renal impairment for the surgical group, which has already been reported in aortic valve surgery [17] , a higher troponin peak in both groups, which was already known to be a predictor of events after cardiac surgery [18] , and postprocedural infectious complications after TAVI, mostly pulmonary infections that have also been previously reported [6] . These results highlight the weight of postprocedural complications on early mortality.
Transcatheter aortic valve implantation and surgery: late survival
Overall 6-year survival was below 50% in both groups, due to both the age and comorbidities of the population studied, with a majority of non-cardiac deaths. This illustrates the weight of comorbidities in these high-risk patients. The 2-year survival rate of 70% for TAVI or surgery is consistent with the literature for patients with a similar high-risk profile [9, 15] . In non-adjusted analysis, long-term survival seemed to favour surgical management (40 vs 32%, P = 0.03 at 6-year follow-up), but after adjustment on Charlson comorbidity index, the difference was no longer significant between the two groups. This confirms that the initial difference in survival was due to non-comparable risk profiles between patients and not attributable to the procedure itself. Patients in the TAVI group certainly presented with more comorbidities, in particular twice the incidence of cardiac surgery, a higher systolic PAP and more frequent diabetes, than patients in the surgical group. Moreover, the Heart Team evaluation takes into account comorbidities not included in the usual risk scores, such as 'frailty' or chest radiation therapy, which are known poor prognosis factors, and usually lead to favour TAVI over surgery [2, 10, 19] . This illustrates the importance of randomized studies to truly compare the efficacy of the two techniques, with two recent publications showing the non-inferiority or even superiority of TAVI over surgery in high-risk patients [7, 13] . These studies, however, include only selected patients and thus do not reflect everyday life, in contrast to registries. Information from both types of studies is thus complementary and necessary.
Predictive factors of late mortality. In the surgical AVR group, we identified a history of cancer, COPD, significant coronary artery disease, lower haemoglobin level and postoperative systolic PAP as predictors of late death. In the TAVI group, we also found a history of cancer, the presence of diabetes and the functional NYHA class as preprocedural variables and Day 7 echocardiographic data, in particular periprosthetic AR ≥ 2/4, as predictors of late death.
In the Canadian registry, predictors of 4-year mortality were the presence of AF, COPD and renal insufficiency [5] , whereas Toggweiler et al. [20] reported COPD and periprosthetic AR ≥ 2/4 as predictors of 5-year mortality.
Even if our results show certain differences with other longterm follow-up registries, we found two major determinants of long-term outcomes: the weight of patients' comorbidities on the one hand and the quality of immediate procedural results on the other hand. These results may help patient selection and improve follow-up modalities but have to be interpreted with caution given the limited number of patients. 
Medical treatment group
The particularly poor prognosis of medically treated patients illustrates the natural history of untreated symptomatic AS. It should also be interpreted according to the extreme gravity of the situation for these patients. This is illustrated by a drop in the overall survival curve from the beginning of the follow-up, with a 1-year survival rate of only 30% (Fig. 2) . This rate is much lower than the reported 50 and 60% survival rates in previous studies [19, 21] . This may be explained by more advanced cardiac disease with lower LVEF and higher systolic PAP when compared with the PARTNER trial, even though the risk scores were close [19] .
Percutaneous balloon aortic valvuloplasty
In this study, 65 patients had a PBAV, either as a bridge while waiting for AVR (49%) or for compassionate reasons (51%). Among the 33 patients who had a compassionate PBAV, 6 needed urgent non-cardiac surgery, mostly orthopaedic surgery.
The current recommendations for PBAV are as follows:
-patients with haemodynamic instability who are waiting for AVR -or patients who need urgent non-cardiac surgery [2] .
We confirm here the good results of PBAV as a bridge to TAVI or surgical AVR. Long-term survival was indeed not significantly different from that of patients who were treated using TAVI or surgical AVR at first-line treatment, although their haemodynamic status was initially more severe. Poor haemodynamic factors such as NYHA class IV and pulmonary hypertension are known predictors of early mortality after TAVI procedures [5, 22] .
However, the use of compassionate PBAV remains controversial with some studies showing no benefit for survival, whereas others report improved short-term survival [23] [24] [25] . In the present study, we report very poor survival after compassionate PBAV that leads us not to recommend this intervention. Even though it is difficult to contraindicate PBAV in patients in shock, our study shows no improvement in survival compared with drug therapy alone, and even a possible deleterious effect of compassionate PBAV. These results may be partly explained by the extreme risk profile of patients and also by the inherent risks of an invasive procedure. PBAV is an interventional procedure and even though the expected risk is low, it increases in relation to patients' risk profiles. Indeed in this study, we report 6 procedure-related deaths out of the 33 compassionate PBAV procedures. Our results thus strongly suggest that therapeutic abstention and drug management should be favoured in these patients.
Temporal trends
The number of procedures, either percutaneous or surgical, has increased over time, from 41 in 2007 to 132 in 2010. This is mostly related to the dramatic increase in the number of TAVI procedures, but is not accompanied by a decrease in surgical procedures. Over the same period of time, we see a marked reduction in the number of patients contraindicated for TAVI or surgery, whereas the number of TAVI procedures increased. This illustrates the technical progress of TAVI from the initial experience in 2006 to a recognized treatment in 2010. The advent of TAVI thus offers an efficient treatment for patients once considered contraindicated for invasive procedures. Insofar as the risk profile of TAVI patients did not increase over time and even tended to decrease, this also reflects better patient selection.
Study limitations
One of the limitations is the single-centre nature of the study. However, a single-centre study ensures more homogeneity in both patient risk assessment by the Heart Team and performance of the procedures.
Given the limited number of patients, results of the multivariate analysis for the identification of predictive factors of mortality need to be interpreted with caution, especially in the surgical group. Moreover, the absence of randomization leads to significant differences in patients' characteristics, which make inter-group comparisons debatable, if not adjusted on comorbidities. The 6-year survival rate concerns only a few patients, notably due to the extremely high mortality rate in the medical treatment group, as illustrated in Fig. 1 .
Finally, we include our early TAVI experience (from 2006) with first-generation catheters and prostheses, which may negatively influence the results.
CONCLUSION
This series reflects the management of high-risk patients referred for AS in a single centre with all therapeutic resources after evaluation by the Heart Team. Medically treated patients presented with the highest risk scores and the most advanced cardiac disease showed the worst survival rates. Compassionate PBAV did not improve survival compared with drug therapy alone and should therefore not be performed even though it is difficult to deny intervention to patients in shock. There was no difference in early and 6-year survival rates between TAVI and surgery groups, after adjustment for comorbidities. In everyday life practice, patients referred for TAVI had more comorbidities than surgically managed patients. Predictive factors of mortality after AVR were early complications for 30-day mortality, and related to patient comorbidities and to the immediate results of the procedure for late mortality. Finally, with the advent of TAVI, the number of patients referred for their severe symptomatic AS increased over time, without negatively affecting the number of surgical procedures.
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